Ap­peals court puts the fi­nal nail in the cof­fin for Tec­fidera patent, adding to Bio­gen's bur­geon­ing set­backs

In an­oth­er set­back for Bio­gen, the big biotech lost its ap­peal to re­vive a patent for the once-block­buster drug Tec­fidera, mark­ing a like­ly con­clu­sion to the case.

The US Court of Ap­peals for the Fed­er­al Cir­cuit is­sued the rul­ing Tues­day morn­ing, say­ing Bio­gen failed to sat­is­fy the “writ­ten de­scrip­tion” re­quire­ment for patent law. As a re­sult, My­lan-turned-Vi­a­tris will be able to sell its mul­ti­ple scle­ro­sis gener­ic with­out fear of in­fringe­ment and Bio­gen will have to find a new rev­enue dri­ver else­where.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER